J&J Q3 Sales Rise 5.9% to $25.4B; Raises 2026 Guidance Despite Talc Charge
JNJ sits 41% above its 52-week low of $184.66.
Summary
J&J reported Q3 2026 sales of $25.4B (up 5.9%) and raised full-year guidance, while GAAP EPS fell to $0.09 on a $5.5B talc litigation charge. Adjusted EPS was $2.59.
Updates
· Binance News — J&J shares fell more than 5% on Tuesday as MedTech revenue of $8.64 billion missed expectations; CFO cited Gulf defense spending shifts, European austerity, and China pricing pressure.
· Seeking Alpha — J&J shares fell as MedTech revenue missed expectations despite the raised guidance.
Key Events · Earnings and Guidance · JNJ
-
Q3 Sales Rise 5.9% to $25.4B
Reported sales grew 5.9% year-over-year to $25.4 billion, with Innovative Medicine up 7.7% and MedTech up 2.5%. Operational growth was 6.0%.
-
GAAP EPS Hit by $5.5B Talc Charge
GAAP EPS fell 95.8% to $0.09, driven by a $5.5 billion litigation charge for the proposed ovarian talc resolution, plus Firefly Bio acquisition and Sail Biomedicines collaboration costs. Adjusted EPS was $2.59, down 7.5%.
-
Full-Year 2026 Guidance Raised
Management raised reported sales guidance midpoint to $101.2 billion (7.4% growth) and adjusted EPS midpoint to $11.10, up $0.06 from the July 29 guidance of $11.04.
-
OTTAVA and IMAAVY Regulatory Wins
FDA granted market authorization for the OTTAVA robotic surgical system and approved IMAAVY for warm autoimmune hemolytic anemia. RYBREVANT FASPRO received priority review for advanced head and neck cancer.
Analysis · JNJ · Life Sciences
Johnson & Johnson delivered a strong operational quarter with 5.9% reported sales growth to $25.4 billion, but GAAP EPS collapsed 95.8% to $0.09 due to a $5.5 billion talc litigation charge and M&A costs. Adjusted EPS of $2.59 beat the operational trend, and management raised full-year 2026 guidance — reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, up $0.06 from July. The quarter also brought FDA market authorization for the OTTAVA robotic system and approval of IMAAVY, reinforcing the innovation pipeline. The talc charge is a one-time item, but the guidance raise signals underlying business momentum is intact.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JNJ was trading at $259.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $635.6B. The 52-week trading range was $184.66 to $281.07. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.